Higher dose = faster / better results. If 250 mcg of BPC-157 works, 1 mg works four times faster. If 5 mg of tirzepatide loses fat, 15 mg loses three times as much.

A persistent thread in biohacker peptide discussion treats dose as a linear scalar: if 250 mcg of BPC-157 produces a healing signal, 1 mg should produce four times that signal; if 5 mg of tirzepatide loses 16% of body weight, 15 mg should lose 48%. The intuition is familiar from over-the-counter drug classes — 400 mg of ibuprofen does roughly twice what 200 mg does — and gym-culture macro-dosing logic generalizes that linearity to nearly every compound the user encounters. For some peptides the lowest published doses are sub-therapeutic and modest upward titration is reasonable. As a general principle, the linearity intuition is a category error: most of the peptides on this site act on receptors, and receptor pharmacology is sigmoidal, not linear.

Why receptor pharmacology is sigmoidal

Receptors saturate. Once the available population is occupied, increasing ligand concentration cannot recruit additional binding. Downstream second-messenger cascades (cAMP, IP3, β-arrestin recruitment) saturate upstream of that, often at concentrations well below full receptor occupancy. The shape of the dose-response curve for receptor-targeted compounds is therefore sigmoidal: a steep rise across the linear portion, an inflection point, and a plateau. This applies across GPCRs (GHSR-1a, GLP-1R, GIPR, MC4R), receptor tyrosine kinases (VEGFR2), and nuclear receptors alike. The question is not whether the peptides on this site have a ceiling — they do — but where on the curve the practitioner is dosing.

What the SURMOUNT-1 and STEP-1 numbers actually show

Jastreboff et al. 2022, SURMOUNT-1, randomized 2,539 adults to once-weekly subcutaneous tirzepatide 5, 10, or 15 mg, or placebo. Mean weight loss at 72 weeks: −16.0% on 5 mg, −21.4% on 10 mg, −22.5% on 15 mg, versus −3.1% on placebo. Marginal benefit was roughly 1.1% per additional milligram from 5 mg to 10 mg, dropping to roughly 0.2% per additional milligram from 10 mg to 15 mg — about a fifth the slope of the lower-dose segment. Tripling the dose did not triple the weight loss; it produced 41% more loss than the 5 mg arm. Gastrointestinal adverse events did not flatten: nausea ran 24.6% / 33.3% / 31.0% across the three doses, diarrhea 18.7% / 21.2% / 23.0%, vomiting 8.3% / 10.7% / 12.2%, and discontinuation for adverse events climbed from 4.3% on 5 mg to 7.1% on 10 mg. The benefit curve flattens while the adverse-event curve keeps climbing — the textbook sigmoid-versus-linear divergence.

Wilding et al. 2021, STEP-1, established 2.4 mg weekly as the regulatory-grade semaglutide dose on the basis of the prior dose-finding work (O'Neil et al. 2018 Phase 2). The FDA approved 2.4 mg because the marginal benefit above that dose did not justify the marginal adverse-event burden. More recent data — the STEP UP trial exploring 7.2 mg weekly — does show additional weight loss at the higher dose, a reminder that "sigmoidal" is not "completely flat past the inflection." Incremental benefit exists above 2.4 mg but is smaller per milligram than below it, and the adverse-event burden continues to scale.

The GH-secretagogue corpus shows the same shape

Nass et al. 2008 studied MK-677 at 25 mg daily — the dose that emerged from earlier dose-finding work (Chapman 1996) as the level that restored IGF-1 to young-adult range in older adults. No published trial demonstrates that doubling to 50 mg produces additional IGF-1 elevation; somatotroph receptors have a ceiling. What does scale above 25 mg is the appetite, water retention, glycemic shift, and cortisol drift Nass 2008 documented at the standard dose. The MK-677 tolerance myth response walks the parallel pharmacology question around continuous-versus-pulsatile dosing on the same receptor.

For ipamorelin, Raun et al. 1998 reported full GH-releasing potency at doses far below the level at which off-target hormones (ACTH, cortisol, prolactin) begin to elevate. Gobburu et al. 1999 characterized the human dose-response across a 33-fold range and reported a half-maximal GH-production plasma concentration of 214 nmol/L, with GH peaks resolving within six hours at every dose. The peak GH pulse is dose-limited by pituitary somatotroph capacity, not by ligand availability — higher doses widen the receptor-occupancy window without amplifying the pulse height.

GHK-Cu brings a different ceiling. Fibroblast collagen-synthesis dose-response peaks around 10⁻⁹ M in dermal-fibroblast culture, vastly below systemic-equivalent levels in injectable protocols. Above roughly 10 mg/day systemic-equivalent, the dose-limiting concern shifts from the GHK signaling effect — which has already saturated — to the copper load. The IOM upper-limit threshold for total dietary copper is 10 mg/day for adults.

BPC-157 practitioner-reported optimal doses cluster around 250 to 500 mcg twice daily across the case-series and observational landscape. There is no published human trial demonstrating that 1 mg or 2 mg outperforms that range, and the rodent work the molecule's evidence rests on — Krivic et al. 2006, Klicek et al. 2008, Sikiric et al. 2018 — was conducted at doses that scale to the lower end of the practitioner range, not the higher.

β-arrestin desensitization and adverse-event super-linearity

Sustained or supramaximal agonism of G-protein-coupled receptors recruits β-arrestin to the agonist-occupied receptor, triggers internalization through clathrin-coated pits, and produces either receptor degradation or recycling depending on the specific receptor and ligand. The general pharmacology lineage from Lefkowitz and Bohn established this as a class principle for GPCRs; Müller et al., Mol Metab 2015, 4:437–460 reviews the application to GHSR-1a specifically. Higher doses do not just produce diminishing benefit; they actively shift the receptor population toward desensitization — the molecular machinery underlying acute tachyphylaxis. The bigger-faster intuition gets the cost direction backwards.

Adverse events scale faster than benefit. Across the GLP-1 class, gastrointestinal adverse-event rates scale roughly 2 to 4 times per dose doubling against weight-loss benefits that scale sub-linearly. Injection-site reactions, cortisol and prolactin spillover on first-generation GHRPs, PT-141 transient blood-pressure elevation, and MOTS-c centrally mediated effects all show non-linear adverse-event escalation alongside flattening benefit curves. The therapeutic-index ratio — benefit dose versus toxicity dose — erodes in both directions at high doses.

Time-on versus dose

For healing peptides especially, time-on at therapeutic dose has stronger published signal than dose escalation. The cyclical 4-to-8-week protocols at modest doses that dominate practitioner BPC-157 and TB-500 use are mechanistically defensible — repeated exposure across a tissue-repair window lets the angiogenic and matrix-remodeling biology unfold. Doubling dose to compress timeline rarely is, because the rate-limiting step is tissue biology, not drug exposure. The healing and angiogenesis dossier walks the time-course logic.

The honest exceptions

The page would be misleading without naming the cases where dose escalation does produce additional benefit. Tesamorelin is approved at 2 mg daily on the basis of Falutz et al. 2007; lower doses underperform in dose-finding work. Retatrutide showed a stepped dose-response in Jastreboff et al. 2023 — −8.7%, −17.1%, −22.8%, −24.2% on 1, 4, 8, and 12 mg at 48 weeks — though even that curve flattens between 8 mg and 12 mg (a 1.4 percentage-point gain across a 50% dose increase). PT-141 is approved at 1.75 mg subcutaneous on the basis of Kingsberg et al. 2019; doses below that are sub-therapeutic for the labeled indication. The right framing is not "less is always more" — it is "the dose-response curve has a shape, and the shape for most receptor-targeted peptides plateaus well below the upper end of practitioner-forum protocols."

The right framing: peptide dose-response curves are sigmoidal, and most practitioner-circulating protocols already sit at or past the inflection point. Increasing dose past that point spends therapeutic-index margin without proportional benefit. The cases where higher doses do produce more effect — tesamorelin, retatrutide across the studied range, PT-141 at the labeled dose, semaglutide between sub-therapeutic and 2.4 mg — are visible in the published dose-finding literature and are the exception against which the general sigmoidal pattern is calibrated.